stockrowVera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) Free cash flow
Vera Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$241.7M, compared with −$135.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$338.9M. Over the past ten years it has ranged from −$241.7M (fiscal 2025) to −$10.4M (fiscal 2019) — the current reading is the lowest in ten years. Free cash flow has fallen for 4 consecutive fiscal years. Vera Therapeutics, Inc. ranks 574th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$241.7M | — |
| FY2024 | −$135.7M | — |
| FY2023 | −$92.2M | — |
| FY2022 | −$67.7M | — |
| FY2021 | −$28.7M | — |
| FY2020 | −$34.9M | — |
| FY2019 | −$10.4M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$100.4M | — |
| Mar 2026 | −$106.7M | — |
| Dec 2025 | −$70.1M | — |
| Sep 2025 | −$62.0M | — |
| 23 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.0M |
| ADMA ADMA Biologics Inc compare | $140.5M |
| VCEL Vericel Corporation compare | $57.9M |
| PVLA Palvella Therapeutics, Inc. compare | −$36.5M |
| IMNM Immunome, Inc. compare | −$219.1M |
| CLDX Celldex Therapeutics, Inc. compare | −$242.1M |
| VERA Vera Therapeutics, Inc. | −$338.9M |
| BHVN Biohaven Ltd. compare | −$473.2M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$524.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)